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Abstract 
Due to the low absorptivity of bile acids, the aim of this study was to develop and 
validate a simple and sensitive HPLC/UV method for quantification of ursodeoxycholic acid 
(UDCA) in pharmaceutical formulations. Effective separation was achieved on C18 end–
capped column, with gradient elution of a mobile phase composed of 0.001 M phosphate buffer 
(pH 2.8±0.5) – acetonitrile mix, at flow rate 1.5 mL min-1, UV detection at 200 nm and injection 
volumes were 50 µL. The proposed HPLC method was fully validated according to the ICH 
guidelines and it was found to be simple, accurate, precise and robust. 
 




Bile acids are natural products i.e. they are terminal endogenous catabolism products 
of cholesterol and play a crucial role in cholesterol homeostasis, lipid absorption and 
production of bile flow. According to their origins, bile acids can be divided into primary and 
secondary (Qiao et al., 2012). Primary bile acids are cholic acid (CA) and chenodeoxycholic 
acid (CDCA), while deoxycholic acid (DCA) and lithocholic acid (LA) are secondary bile 
acids. In addition, CDCA is partially epimerized into tertiary bile acid called ursodeoxycholic 
acid (UDCA), which represents a group of "minor" bile acids that have significant importance 
(Stamp and Jenkins, 2008). UDCA is a known, safe and efficacious drug that has been widely 
used for oral gallstone dissolution therapy (Mas et al., 2007). 
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The IUPAC chemical name of UDCA is 3α, 7β-dihydroxy-5β-cholan-24-oic acid, with 
an empirical formula C24H40O4 and a molecular weight of 392.64 g/mol. It has an appearance 
of white powder with a bitter taste. It is freely soluble in ethanol and glacial acetic acid, slightly 
soluble in chloroform, sparingly soluble in ether, and practically insoluble in water, with pKa 
~ 4.66 (Soni Varinder et al., 2015a). UDCA (7β–position) is an epimer of CDCA (7-position) 
and due to this structural modification, is less hydrophobic, detergent and toxic bile acid. (Roda 
et al., 1995). 
The USP and Ph. Eur. official monographs refer to an HPLC method with a refractive 
index detector or a TLC method for the analysis of UDCA in raw materials. In literature, there 
are other methods described for determination of UDCA, such as: HPLC methods coupled to 
MS (Raghunadha Reddy, 2010) and evaporative light-scattering mass detection (Roda et al., 
1992), GC methods coupled to MS (Courillon et al., 1997), and capillary electrophoresis 
method or micellar electrokinetic chromatography (Rodrıǵuez et al., 2000). However, these 
methods require a high sample amount and the instruments required are not a common 
laboratory equipment. 
To the best of our knowledge, for determination of UDCA in raw material and 
pharmaceuticals the application of UV detector is limited due to the low absorptivity of bile 
acids. Therefore, the aim of our work was to develop and validate a simple and sensitive 
HPLC/UV method for quantification of UDCA in solid pharmaceutical formulations that could 
be applied in quality control laboratories.  
 
Materials and methods  
Chemicals, reagents and HPLC instrumentation 
UDCA, CA, CDCA and LA standard substances, used in the study, were provided by 
EDQM. The pharmaceutical dosage forms, hard capsules containing UDCA (150 mg/capsule), 
were obtained from the commercial market. Acetonitrile and methanol were HPLC-grade, and 
purchased from Merck (Darmstadt, Germany). Phosphoric acid, potassium phosphate 
monobasic anhydrous and formic acid were supplied from Sigma-Aldrich (St. Louis, MO, 
USA). Double-distilled water was used to prepare mobile phase solutions. All solutions were 
filtered through a 0.45 μm (pore size) nylon membrane filter and vacuum degassed before use.  
HPLC analyses were performed using a Schimadzu LC-2010 chromatographic system 
(Schimadzu, Kyoto, Japan). Chromatograms were processed using Class VP 7.3 Software. 
 
Chromatographic Conditions 
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Effective chromatographic separation was achieved using a LiChroCART® 
Purospher® STAR RP–18 end–capped column (150 x 4.6 mm i.d., particle size 5 μm) as 
stationary phase with gradient elution of a mobile phase composed of 0.001 M potassium 
phosphate buffer (adjusted to pH 2.8±0.5, using phosphoric acid) and acetonitrile (ACN). A 
linear gradient was used (0–35 min, 40–80% ACN; 35–35.01 min, 80–40% ACN; and 35.01–
41 min, 40% ACN). The column temperature was maintained at 40 °C. The flow rate was 1.5 
mL min-1 and the detection wavelength was set at 200 nm. The injection volumes were 50 µL. 
 
Preparation of solutions 
Standard Mix Solution (target working concentration of 0.6 mg mL-1 of all bile acids 
standards, UDCA, CA, CDCA and LA) was prepared by transferring 2 mL from each stock 
standard solution to a 10 mL volumetric flask and diluting with a same dilution solvent up to 
mark. Stock standard solutions were prepared by dissolving UDCA, CA, CDCA and LA (30 
mg) consequently with 10 mL dilution solution.  
As dilution solvent was used an acidified methanol with 0.05% formic acid (in a ratio 
of 75:25, v/v), pH 3.0 of solution. 
Sample solution was prepared as follows: twenty capsules containing 150 mg UDCA 
were weighed accurately, the capsule content was mixed, homogenized and a capsule powder 
equivalent to 150 mg UDCA was used and diluted with dilution solvent to obtain a working 
concentration of 0.6 mg mL-1 UDCA. Sample solution was filtered through a membrane filter 
0.45 μm (pore size) prior to injecting into the HPLC system. 
 
Results and discussion 
 
In order to establish an efficient, selective and fit for purpose analytical method with 
optimum resolution between UDCA, related substances and excipients, several method 
variables were employed, such as use of different HPLC columns, different compositions and 
pH of mobile phase, and different concentrations of standard and sample solutions. We used 
HPLC RP-18 columns from different manufacturers with various lengths (25.0, 15.0, 12.5 and 
10.0 cm) and constant internal diameter of 4.6 mm, but we obtained a poor peak shape. Finally, 
a LiChroCART ® Purospher® STAR RP – 18 end–capped column, 150 x 4.6 mm i.d., particle 
size 5 μm (Merck, Germany) was chosen for the study as an excellent peak shape was obtained. 
Column temperature was maintained at 40 °C. 
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Acetonitrile was chosen in the mobile phase because of its absorbance (UV cut off) at 
low wavelengths, while a phosphate buffer with pH 2.8 enables UDCA to elute in its molecule 
form. Due to the low UV response of bile acids, the UV detector was set at 200 nm at which 
the studied molecules gave a satisfactory absorbance and representable chromatogram (Fig. 1b, 
St mix) (Boscolo et al., 2017).  
All samples and standards were diluted in an acidified methanol with formic acid 
(methanoic acid), pH 3.0 of solution, in order to ensure the molecular forms of UDCA and 
related substance. 
 Dwell volume is important parameter for gradient elution, because of its greatest effect 
on retention times of substances that are not strongly retained. Dwell volume (0.57) was 
calculated according to the recommendation of the European pharmacopeia (Ph. Eur., 2.2.46), 
which means the proposed linear gradient elution is suitable. In order to achieve good peak 
shape, symmetry, and the highest resolution of UDCA and its related impurities, the flow rate 
was set at 1.5 mL min-1 and HPLC injection volumes were 50 µL. 
 UDCA was identified based on the retention time as compared with the UDCA 
standard. As shown in the chromatogram, the method is capable of separating UDCA in the 
presence of the related impurities (Fig. 1b). Furthermore, with the proposed method we 
obtained a comparable sensitivity (with suitable limit of detection (LoD) of 0.099 µg mL-1 and 
limit of quantification (LoQ) of 0.303 µg mL-1) with the sensitivity obtained in the published 
HPLC methods coupled to refractive index detector (Varinder et al., 2015b). 
 
 Fig. 1. 
 
Method validation 
Method validation was performed following the ICH Harmonized Tripartite Guideline; 
Validation of Analytical Procedures: Text and MethodologyQ2(R1) (ICH, 2005). 
 
System suitability 
The most important SST (system suitability) parameters which are investigated for 
HPLC analyses are: resolution (R), repeatability or reproducibility (relative standard deviations 
(RSD) of peak response and retention time), column efficiency or plate count (N) and tailing 
factor (T) (Bose, 2014).   
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The system suitability parameters were calculated according to the recommendation of 
the United States Pharmacopoeia and reported as RSD of peak response and retention time 
(USP, <1225>; <621>).  
We assessed the system repeatability by 6 consecutive injections of standard UDCA 
solution with concentration of 0.6 mg mL-1.   
The relative standard deviations (RSDs = 0.38%) of the UDCA peak area of standard 
and resolution solutions satisfy the acceptance criteria (Fig. 1b). Furthermore, the proposed 
method was found to be suitable in terms of efficiency (10835.16); tailing factor (0.96) and 
resolution (4.40) between UDCA (as main peak) and CA (its closest peak) according to USP 
(<621>). Relative retention time (RRT) also known as the “unadjusted relative retention” is 
defined as the ratio of the retention times of any component to the retention times of reference 
compound.  
Relative retention times (RRT) in relation to UDCA (Fig. 1b) were found to be: RRT 
is 0.7 for CA (Rt CA = 4.752 min), RRT is 1.5 for CDCA (Rt CDCA = 9.771 min) and RRT 
is 3.0 for LA (Rt LA = 19.408 min) according to USP (<621>).  
 
Specificity and selectivity 
Specificity ensures the identity of an analyte of interest. It is demonstrated by the ability 
to discriminate between compounds of closely related structures, or by comparison to known 
reference materials. The specificity of the HPLC method was accomplished with the complete 
separation of UDCA in the presence of related bile acids and excipients used to formulate and 
produce these hard capsules. In addition, there was not any interference observed at the 
retention time of UDCA in the chromatogram of blank solution (Fig. 1). 
Peak purity of the sample solution was higher than 99.8%, demonstrating that other 
compounds did not co-elute with peak of interest. 
 
Linearity and range 
Linearity was determined in the range of 0.12–1.05 mg mL-1 for UDCA. The correlation 
coefficient (r) observed was 0.9999. Typically, the regression equation for the calibration curve 
was found to be 740023x + 2104.5, with standard errors of intercept 1665.2 and slope 2680.5. 
The results of the regression statistics indicate that the method is linear over the 
concentration range studied. 
 
Precision and Accuracy 
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Precision was evaluated in terms of repeatability and intermediate precision. 
Repeatability was assessed using six separate sample solutions at 100% of the test 
concentration (0.6 mg mL-1 UDCA) on the same equipment and on the same day. 
The intermediate precision was calculated using six sample solutions, prepared at the 
same conditions, over three consecutive days. The RSD values were calculated from the 
retention time and peak areas, respectively of UDCA of the series of measurements (Sheng et 
al., 2018). 
The variation in the results obtained for UDCA determination within a day (intra-assay 
precision) (RSD = 0.58% and RSD = 0.37%, of retention time and peak area, respectively) and 
day to day variations (intermediate precision) (RSD = 0.27% and RSD = 0.16%, of retention 
time and peak area, respectively) was very low (≤ 2%), thus confirming the precision of the 
method. 
The accuracy of the HPLC analysis was determined by spike recovery. To discover 
whether excipients interfered with the analyte, sample solutions were spiked with different 
known amounts of UDCA standard solution (25%, 50%, 75%, 100%, 125% and 150%). The 
percent of recovery was calculated using the calibration equation. 
Recovery values (Table 1) obtained from the determination of UDCA in commercial 
hard capsules using the method of standard additions confirmed that the method was accurate 




Limit of detection and limit of quantitation 
LoQ and LoD were determined to evaluate the sensitivity of the proposed method.  LoD 
(also called detection limit) is defined as the smallest amount or concentration of analyte in the 
test sample that can be reliably distinguished from zero, while LoQ is defined as the lowest 
concentration of analyte that can be determined with an acceptable repeatability and trueness 
under the stated operational conditions of the method. 
In order to access LoD and LoQ, UDCA standard solutions were diluted to obtain lower 
concentrations in a range of 0.289 µg mL-1 to 25.023 µg mL-1 and injected onto the 
chromatographic system.  
LoD and LoQ were calculated with regression statistical analysis of the calibration 
curve obtained with the low concentrations of UDCA, using the ratio 3.3 SD/S and 10 SD/S 
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respectively, where SD is standard deviation of the response based on the standard deviation 
of y-intercepts of regression lines and S is slope of the calibration curve (ICH, 2005). 
The LоD and LоQ for UDCA were 0.099 µg mL-1 (99 ng mL-1) and 0.303 µg mL-1 (303 
ng mL-1), respectively. 
 
Robustness 
Robustness which is a definition for the capacity of a method is a measure of the 
reliability of a method. Robustness of the method was investigated by varying the instrumental 
conditions such as variations in the pH of mobile phase (± 0.2), column temperature (± 5 oC), 
while maintaining the same operational and environmental conditions. The obtained values for 
tailing factor were within the acceptable limits (˂ 2), as well as the obtained standard deviations 
of the retention time of main peak (≤ 1.5%) were found to be in the acceptable range (USP, 
˂621>).  The results show that the small and deliberate variations in the column temperature, 




The validated method was applied for determination of UDCA in commercially 
available hard capsules containing 150 mg UDCA. The results obtained indicate that the 
proposed RP-HPLC method with UV detection was found to be specific, sensitive, accurate, 
precise and robust for determination of UDCA in pharmaceutical dosage forms. 
Furthermore, results from LoD and LoQ, and the chromatogram obtained from standard 
mix solution (Fig. 1b) illustrates an acceptable resolution between UDCA and CA as closest 
eluted peaks and demonstrated that the proposed method is capable to separate and to 
accurately determine the active substance UDCA in the presence of related bile acids (CA, 
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Резиме 
 
Валидиран RP-HPLC метод со УВ детекција за определување на урсодеоксихолна 
киселина во фармацевтски формулации 
 
Жаклина Попоска Свиркова1*, Зорица Арсова-Сарафиновска1, Александра Грозданова2 
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Клучни зборови: урсодеоксихолна киселина, HPLC/UV, фармацевтски дозирани 
форми, валидација на метод  
 
Поради ниската апсорпција на жолчните киселини, имавме за цел да се развие и 
валидира едноставен и чувствителен HPLC/UV метод за определување на 
урсодеоксихолна киселина (UDCA) во фармацевтски производи. Ефективно 
раздвојување се постигна на C18 „end–capped” колона, со градиентно елуирање на 
мобилната фаза составена од мешавина на 0,001 М фосфатен пуфер (pH 2,8±0,5) и 
ацетонитрил, со проток 1,5 mL min-1, UV детекција на 200 nm и волумен на инјектирање 
50 μL. Предложениот HPLC/UV метод беше целосно валидиран според упатствата на 
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0.150 0.154 102.71 101.96 – 103.45 0.29       2.71 
0.300 0.305 101.77 100.24 – 103.29 0.61  1.77 
0.450 0.463 102.85 100.92 – 104.77 0.75 2.85 
0.600 0.607 101.15 99.36 – 102.94 0.71 1.15 
0.750 0.753 100.34 99.05 – 101.62 0.52 0.34 
0.900 0.898 99.82 98.06 – 100.91 0.58 -0,18 
 101.44 100.14 – 102.74 0.58 1.44 
 
1 Mean value (n=3) of amount added of UDCA standard solution to sample solutions with working 
concentration 0.6 mg mL-1 
2 Mean value (n=3) of amount found of UDCA standard solution in sample solutions with working 
concentration 0.6 mg mL-1 
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Fig. 1. Typical chromatograms of: (a) ursodeoxycholic acid standard solution; (b) 
ursodeoxycholic acid standard mix solution of UDCA and related bile acids, CDCA, CA and 
LA; (c) ursodeoxycholic acid capsule 150 mg sample solution; (d) blank solution. 
 
